Clinical trials: Pancreas Tumor
Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial
This phase II trial compares the effect of combination therapy with capecitabine and temozolomide to lutetium Lu 177 dotatate for the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body…
- Trial name
- NCT05247905
- Testing
- Lutetium Lu 177 Dotatate, Capecitabine, Temozolomide
- Where
- 171 sites in United States
- Volunteers
- 31 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Solid Tumor, Gastric Cancer
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05156866
- Testing
- TORL-2-307-ADC
- Where
- 12 sites in United States, South Korea
- Volunteers
- 163 people
- Sponsor
- TORL Biotherapeutics, LLC
Pancreatic Cancer
Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma
This study aims to evaluate the prognostic impact of the detection of circulating tumor DNA in peripheral venous blood, portal venous blood, collected intraoperatively, as well as its detection in peritoneal fluid.
- Trial name
- VEINOPAN (NCT06478056)
- Testing
- pancreatectomy
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Rouen
Pancreatic Cancer
Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma
The research purpose of this project is to create a registry, and blood and tissue bank for individuals at high-risk for pancreatic cancer.
- Trial name
- NCT01219829
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Columbia University
Localized Non-Resectable Adult Liver Carcinoma
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study
This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal…
- Trial name
- RESiN (NCT02685631)
- Testing
- Yttrium-90 Resin Microspheres
- Where
- 42 sites in United States
- Volunteers
- 1,653 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Pancreatic Cancer
Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial)
The study will examine if a multi-modal nutritional care package, with or without resistance training delivered with neoadjuvant chemotherapy, is effective at preventing loss of muscle strength during neoadjuvant chemotherapy for…
- Trial name
- FEED (NCT06149546)
- Testing
- Control, Intervention
- Where
- Ireland
- Volunteers
- 70 people
- Sponsor
- Cancer Trials Ireland
Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy
Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer
The aim of this study is to evaluate the advantage of mesenteric approach during pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, Mesenteric Approach
- Trial name
- NCT03317886
- Testing
- pancreaticoduodenectomy
- Where
- 15 sites in Japan
- Volunteers
- 354 people
- Sponsor
- Wakayama Medical University
Colorectal Cancer, Esophageal Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer
RATIONALE: LMB-9 immunotoxin can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced pancreatic, esophageal, stomach, colon or rectal cancer.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00010270
- Testing
- LMB-9 immunotoxin
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Freiburg
Biliary Tract Neoplasms, Pancreatic Neoplasms
Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)
This study compares the 6 mm nitinol Zilver biliary endoprostheses and the 10 mm nitinol Zilver biliary endoprostheses to the 10 mm Wallstent in appropriate patients in need of palliative treatment of malignant obstructive…
- Conditions
- Biliary Tract Neoplasms, Pancreatic Neoplasms, Jaundice, Obstructive
- Trial name
- NCT00196105
- Testing
- 6 mm Nitinol Zilver Stent, 10 mm Nitinol Zilver Stent, 10 mm Stainless Steel Wallstent
- Where
- United States
- Volunteers
- 241 people
- Sponsor
- Cook Group Incorporated
Cancer, Pancreatic Cancer
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
The objectives of this study are: To determine the safety and MTD of CPI-613, when used in combination with Gemcitabine, in cancer patients. To compare the safety and efficacy of CPI-613/Gemcitabine combination vs.
- Conditions
- Cancer, Pancreatic Cancer, Pancreatic Carcinoma
- Trial name
- NCT00907166
- Testing
- CPI-613, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Cornerstone Pharmaceuticals
Pancreatic Ductal Adenocarcinoma (mPDAC), Pancreatic Head Tumour
Immunoparalysis After Pancreaticoduodenectomy
By 2030, pancreatic adenocarcinoma could become the second leading cause of cancer-related death in France. To date, Pancreaticoduodenectomy (PD) is the standard treatment for resectable adenocarcinoma of the pancreatic head.
- Conditions
- Pancreatic Ductal Adenocarcinoma (mPDAC), Pancreatic Head Tumour, Pancreatic Fistula
- Trial name
- ImPaHLA (NCT07144917)
- Testing
- mHLA-DR analysis
- Where
- 4 sites in France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Pancreatic Cancer
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for pancreatic cancer.
- Trial name
- NCT06601010
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Pancreatic Cancer
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
The purpose of the study is to determine the optimal safe and tolerable dose of gemcitabine in combination with once daily or twice daily dose of PTK/ZK in patients with unresectable pancreatic cancer.
- Trial name
- NCT00185588
- Testing
- Vatalanib, Gemcitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- George Albert Fisher
Metastatic Pancreatic Cancer
Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity
It will be investigated whether it is possible to predict the effect or lack of effect of first-line treatment by analysing cancer cells from the individual patient receiving standard first line treatment.
- Trial name
- TIP (NCT03821870)
- Testing
- Inditreat, Experimental drug
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Vejle Hospital
Pancreas Cancer, Periampullary Cancer
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Adjuvant chemotherapy after surgery significantly improved the survival of pancreatic cancer (PC) patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy.
- Conditions
- Pancreas Cancer, Periampullary Cancer, Periampullary Carcinoma Resectable, Pancreatic Cancer Resectable
- Trial name
- NCT07081360
- Testing
- Neoadjuvant chemotherapy, Upfront Surgery Group
- Where
- Egypt
- Volunteers
- 262 people
- Sponsor
- Minia University
Pancreatic Neoplasms
EUS-FNB With MOSE vs EUS-FNA With ROSE
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is an indispensable tool for tissue acquisition for pancreatic lesions.
- Trial name
- MORE (NCT03766659)
- Testing
- MOSE, ROSE
- Where
- Hong Kong
- Volunteers
- 340 people
- Sponsor
- Chinese University of Hong Kong
Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Conditions
- Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer
- Trial name
- NCT05005403
- Testing
- Azirkitug, Budigalimab, Bevacizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 694 people
- Sponsor
- AbbVie
Adenocarcinoma, Pancreatic Neoplasms
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
The purpose of this study is to evaluate the clinical activity of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma, Pancreatic Neoplasms, Neoplasm, Glandular, Neoplasms
- Trial name
- NCT03535727
- Testing
- Nab-paclitaxel, Gemcitabine, Capecitabine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Solid Tumors
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced solid tumors. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and…
- Trial name
- NCT01302405
- Testing
- PRI-724
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Prism Pharma Co., Ltd.
Resectable Pancreatic Cancer
Borderline Pancreas Study: FOLFIRINOX +SBRT
Primary Objective: To determine the rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy. Secondary Objective(s): 1.
- Trial name
- GCC 1324 (NCT01992705)
- Testing
- Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85 mg/m2 IV on Day 1, -Irinotecan 180 mg/m2 IV on Day 1
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Maryland, Baltimore
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.